NCT01591447View on ClinicalTrials.gov

Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
DRUG

solithromycin

A single oral dose of 1200 mg solithromycin (CEM-101)

DRUG

Solithromycin (CEM-101)

A single oral dose of 1000 mg solithromycin

Trial Locations (2)

35233

Jefferson County Department of Health, Birmingham

98104

Harborview STD Clinic, Seattle

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY